Chemotherapy for alpha-fetoprotein producing gastric cancers expressing human epidermal growth factor receptor 2. Issue 4 (April 2018)

• Record Type: Journal Article
• Authors: Hayashi, Kazumi; Nagasaki, Eijiro; Nakada, Koji; Tamura, Miho; Arakawa, Yasuhiro; Uwagawa, Tadashi; Yano, Shingo
• Is Part Of: Journal of infection and chemotherapy. Volume 24:Issue 4(2018:Apr.)
• Page Start: 298
• Page End: 301
• Publication Date: 2018-04
• Subjects: HER2 -- AFP -- Gastric cancer -- Chemotherapy; Chemotherapy -- Periodicals; Infection -- Periodicals; Communicable diseases -- Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1016/j.jiac.2017.10.019
• Languages: English
• ISSNs: 1341-321X

Abstract

Abstract: Although, gastric cancer is one of the most common cancers worldwide, alpha-fetoprotein (AFP) producing human epidermal growth factor receptor 2 (HER2) positive gastric cancers are rare. AFP producing gastric cancer has a poor prognosis and an appropriate treatment option has not been established to date. A 75-year-old woman with AFP- producing gastric cancer was treated with S-1, an oral fluoropyrimidine derivative, chemotherapy after distal gastrectomy. Recurrence of gastric cancer was observed after 18 months and immunohistochemistry analysis showed AFP and HER2 positive gastric cancer. The patient received combination therapy containing capecitabine, cisplatin, and trastuzumab. Computed tomography scans showed regression of the lymph node metastasis. The patient's quality of life substantially improved after the treatment. Thus, the present case suggests that AFP and HER2 positive gastric cancer can be effectively treated with, capecitabine, cisplatin, and trastuzumab combination therapy.